Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.W | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Dr. Black article on Phase 2 Trial of Atezolizumab

<< Previous

Bullboard Posts

Next >>

Comment by enriquesuaveon Aug 23, 2023 3:54pm

159 Views

Post# 35602564

RE:RE:Dr. Black article on Phase 2 Trial of Atezolizumab

Adstiladrin 12 months CR is about 24%. We are beating them badly. ( 46% of the 51% who are CR remain so at 12 months, so it's not 46% but 23.5%). . We may end up with double that, and much simpler manufacturing and less side effects, as well as less treatments.

<< Previous

Bullboard Posts

Next >>

What is renewable energy's role in the future energy equation?